Novartis Opens New Radioligand Therapy Facility in California
Novartis AG has opened a new 10,000-square-foot radioligand therapy manufacturing facility in Carlsbad, California, marking its third RLT site in the US. This expansion is part of a $23 billion investment in US infrastructure over five years, which includes new facilities in Florida and Texas, and expansions in North Carolina, Indiana, and New Jersey. Additionally, Novartis plans to establish a biomedical research innovation hub in San Diego, emphasizing its commitment to enhancing cancer care and strengthening US operations.
Novartis AG has announced a major expansion of its radioligand therapy (RLT) manufacturing capabilities in the United States, highlighted by the opening of a new 10,000-square-foot facility in Carlsbad, California. This site marks the company’s third dedicated RLT manufacturing location in the US and is part of a broader $23 billion investment in US infrastructure over the next five years. Additional plans include new RLT manufacturing facilities in Florida and Texas, as well as expansions at existing sites in North Carolina, Indiana, and New Jersey. Novartis also revealed plans for a new biomedical research innovation hub in San Diego. These initiatives underscore the company’s commitment to advancing cancer care and strengthening its US operations. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001137867-en) on November 10, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
